Aprogen Biologics에이프로젠바이오로직스
003060 · KOSPI · ₩003060 · 에이프로젠바이오로직스
- Market cap
- ₩40B
- Enterprise value
- ₩208B
- P/E
- —
- P/B
- 0.2×
- Dividend yield
- 0.0%
- ROE
- −40.3%
- Net margin
- −90.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−86.9% from the high
₩1,369Today: ₩1,369 – ₩1,440₩10,566
Returns
- 1W−5.1%
- 1M−15.4%
- 3M−32.2%
- 6M−65.3%
- YTD−83.2%
- 1Y−84.3%
- Volume today
- 47,488
- 0.4× the 20-day average
- Traded today
- ₩65M
- Listed shares
- 28,967,684
- EPS (12 months)
- −₩2,703
- Earnings yield −194.9%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 29 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Only a routine shareholding filing, which is neutral. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-13.4% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Aprogen Biologics stock overview
Aprogen Biologics (에이프로젠바이오로직스, KRX: 003060) is listed on KOSPI, in the Biotech & Pharma sector. Aprogen Inc. Its shares closed at ₩1,387 on Oct 27, 2026, up 0.58% on the day, giving it a market value of ₩40B.
Key facts
- Market cap
- ₩40B
- Sector
- Biotech & Pharma
- Latest price change
- +0.58%
- As of
- Oct 27, 2026
- Main business
- Aprogen Inc.
Quick answers about Aprogen Biologics
- What does Aprogen Biologics do?
- Aprogen Inc. is a Korean pharmaceutical company that manufactures and sells generic prescription drugs, such as circulatory, central nervous system, digestive, and metabolic medicines, from its plant in Hwaseong, Gyeonggi Province. Through its Osong, Chungbuk plant, it also provides biopharmaceutical manufacturing services for antibody drugs, and its subsidiary Aprogen Pharma distributes medicines to wholesalers, hospitals, clinics, and pharmacies.
- What is the market cap of Aprogen Biologics?
- The market capitalisation of Aprogen Biologics was ₩40B at the close on Oct 27, 2026.
- Who are the largest shareholders of Aprogen Biologics?
- According to the latest official filings, the largest reported holders are Aprogen (91.63%, as of Oct 8, 2026); Lee Young-cheol (0.82%, as of Jun 24, 2026); National Pension Service (0.08%, as of Dec 31, 2025).
- When is the next earnings report from Aprogen Biologics?
- Korean companies rarely announce results dates in advance. Based on when Aprogen Biologics filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
- Does the National Pension Service own Aprogen Biologics?
- Yes. The National Pension Service held 0.08% of Aprogen Biologics shares as of Dec 31, 2025.
Company profile
Aprogen Inc. is a Korean pharmaceutical company that manufactures and sells generic prescription drugs, such as circulatory, central nervous system, digestive, and metabolic medicines, from its plant in Hwaseong, Gyeonggi Province. Through its Osong, Chungbuk plant, it also provides biopharmaceutical manufacturing services for antibody drugs, and its subsidiary Aprogen Pharma distributes medicines to wholesalers, hospitals, clinics, and pharmacies. Since late 2025 it has also consolidated Entwotec, which makes semiconductor equipment parts for chip manufacturing customers at a plant in Anseong, Gyeonggi Province.
Written by AI from the company's latest annual report.
- Korean name
- 에이프로젠바이오로직스
- Sector
- Biotech & Pharma
- CEO
- 김재섭, 김정출
- Founded
- Dec 1960
- Listed
- Oct 1984
- Listed shares
- 28,967,684
- Fiscal year ends
- Month 12
- Website
- www.aprogen-pharm.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- 5%+ holding reportOct 26, 2026
- Decision to Provide Collateral for Third PartyOct 8, 2026
- 5%+ holding reportOct 8, 2026
- Investment Caution Notice (Advance Notice of Risk of Designation as Administrative Issue)Oct 6, 2026
- Change in largest shareholder's holdingsOct 2, 2026
Titles in Korean until English translations are added.
Also known as: Aprogen Biologics / 에이프로젠바이오로직스 / 003060 / KRX:003060
Source: KRX statistical information